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SUMMARY
This case illustrates the importance of multidisciplinary 
counselling and management of pregnancies in women 
with complex medical conditions, especially concerning 
women with cognitive impairment. We present a 
woman with hyperinsulinism/hyperammonaemia (HI/
HA) syndrome. This syndrome is characterised by 
recurrent episodes of hypoglycaemia and elevated 
ammonia levels, which are potentially harmful to 
both the patient and a developing fetus. We describe 
a successful multidisciplinary approach during the 
pregnancy of a mentally challenged patient with HI/
HA syndrome. This case illustrates the importance of 
personalised counselling during the preconception period 
and emphasises to include all disciplines involved in the 
medical and daily care of such a patient. In our case, the 
extensive multidisciplinary care during the preconception 
period, pregnancy, delivery and postpartum period 
resulted in a good maternal and neonatal outcome.
BACKGROUND
Hyperinsulinism/hyperammonaemia (HI/HA) 
syndrome is a rare autosomal dominant metabolic 
disease, characterised by life- threatening hypo-
glycaemia. The gain of function mutations in the 
GLUD1 gene, encoding for the mitochondrial 
enzyme glutamate dehydrogenase (GDH), leads to 
unrestrained insulin production by the β-cells in the 
pancreas and increased ammonia levels (figure 1).1 
Clinically, the disease is characterised by recurrent 
episodes of symptomatic severe hypoglycaemia. 
Seizures are common and may cause cerebral 
damage, resulting in cognitive impairment with 
learning difficulties.2
CASE PRESENTATION
A 29- year- old woman, body mass index 32 kg/m2, 
diagnosed in childhood with HI/HA syndrome, 
suffers from frequently occurring episodes of severe 
hypoglycaemia. In addition, a 15q13.3 deletion was 
detected with psychomotor retardation (IQ 57). She 
can read and lives independently. She is treated with 
diazoxide 100 mg two times per day (for detailed 
information see # in online supplementary file 1), 
chlorthalidone 25 mg two times per day and a strict 
diet. Her diet consists of frequent carbohydrate- 
rich meals, such as regular intake of uncooked 
cornstarch and avoidance of large protein loads. 
After initially limited compliance, several educa-
tional sessions resulted in strict medical and dietary 
management with less hypoglycaemic episodes. 
This reflected in improved biochemical parameters, 
as presented in table 1.
The patient had two previous spontaneous 
miscarriages (6 and 12 weeks of gestational age) 
while avoiding the healthcare system. After her clin-
ical situation improved, she expressed the wish to 
conceive again. Therefore, she was referred to the 
preconception care and counselling team.
Specialised individual preconception care and 
counselling team
If an increased health risk in pregnancy is known for 
the mother and/or fetus, then future parents should 
be referred for specialised preconception counsel-
ling. Effective contraception should be prescribed 
to optimise and ensure proper preconception care 
(eg, optimise the diet and change in medication). To 
increase the effect of and compliance with possible 
interventions, it is important to actively involve 
the partner in the counselling process. Factors that 
need consideration during preconception counsel-
ling and care in patients with severe conditions in 
general and in case of the HI/HA syndrome specifi-
cally are as follows:
1. Effect of the condition on the pregnancy.
HI/HA → maternal hypoglycaemia → intrauter-
ine growth restriction and fetal demise.
2. Effect of the pregnancy on the condition.
First trimester: possible deterioration of hypo-
glycaemia → fetal demise.
Second and third trimesters: progressive insulin 
resistance → increasing glucose levels.
Delivery: possible deterioration of hypoglycae-
mia due to the physical effort of labour.
Post partum: disappearance of insulin resistance 
→ maternal hypoglycaemia and uterus involu-
tion → hyperammonaemia.
3. Risks due to a previous surgical intervention 
for extrauterine pregnancy or intra- abdominal 
complications in the case of caesarean section 
(not applicable to this case).
4. Teratogenic risk evaluation of medication.
Diazoxide → maternal hypotension, fetal brad-
ycardia, negative effect on uterus contractions 
and neonatal hyperglycaemia.
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5. The risks of medication changes/discontinuation necessary 
for pregnancy.
Stop/lower diazoxide dosage: more severe hypoglycaemia. 
Increased need for carbohydrate- rich feeding: maternal 
weight gain.
6. Risks/recurrence of pregnancy complications or adverse 
pregnancy outcome (referral to a clinical geneticist is some-
times advised).
Fetal growth restriction and a 50% chance for the offspring 
to inherit the GLUD1 mutation.
Preconception counselling
After careful consideration, the patient in this case report was 
advised not to become pregnant considering the following. (1) Due 
to fetal risks, diazoxide use should ideally be discontinued, with 
the deterioration of hypoglycaemic episodes as a consequence. (2) 
Medication change and the changing metabolic demands of preg-
nancy could lead to maternal as well as fetal hypoglycaemic health 
risks. (3) The patient has poor disease perception and a small social 
network to rely on. In addition, lowering or discontinuing the 
diazoxide would necessitate an increase in carbohydrate intake, 
leading to accelerated weight gain in an already obese patient. 
Regardless of this advice, she became pregnant and presented 
herself at 9 weeks of gestational age.
TREATMENT
As soon as the pregnancy was known with the treating physi-
cians, a detailed pregnancy and delivery guidance plan was 
constructed by a multidisciplinary team consisting of a gynae-
cologist, a metabolic consultant, the diabetic team, a metabolic 
paediatrician, a neonatologist, an anesthesiologist, a geneticist, a 
dietician and a social worker.
The diazoxide dosage was reduced by 50% to 100 mg/
day because of the association with fetal risks of intra-
uterine growth restriction, transient fetal bradycardia and the 
unknown effect on fetal neurodevelopment (for detailed infor-
mation see ¥ in online supplementary file 1).3 Her diet was 
adjusted with an increased intake of slow- release carbohydrate 
to a total protein intake of 0.71 g/kg (for detailed information 
see ** in online supplementary file 1). Invasive prenatal diag-
nostics were offered due to the 50% probability of passing on 
the GLUD1 mutation but were declined by the patient and her 
partner.
Figure 1 Figure was drawn by Schoenmakers. It shows regulations and interactions by nutrients and drugs (diazoxide and somatostatin) in 
pancreatic β-cells and hepatocytes on insulin and ammonia (NH3) production. In HI/HA syndrome, the activity of the mitochondrial enzyme glutamate 
dehydrogenase (GDH) is increased, which leads to inappropriate high insulin secretion by the β-cells and ammonia production in all body cells. In the 
ß-cell, GDH is activated by leucine to trigger insulin release in response to a protein- rich meal. This figure also shows how increased catabolism of 
glutamate results in HA, but the ‘normal’ functioning urea cycle in hepatocytes prevents severe HA. Mild elevations of ammonia due occur in patients 
with HI/HA, most likely due to a relative deficiency in (urea cycle stimulating) N- acetylglutamate (because of low levels of its precursor glutamate), 
which reduces the urea cycle capacity to metabolise ammonia. It is identified that the molecular dysfunction caused by GDH S445L mutation is 
responsible for HI/HA.2 HI/HA, hyperinsulinism/hyperammonaemia.
Table 1 Overview of biochemical monitoring and treatment before, during and after pregnancy in a patient with hyperinsulinism/
hyperammonaemia syndrome
Normal range Prepregnancy Pregnancy trimester Labour Post partum
First Second Third
Glucose (mmol/L)* 4.0–6.1 3.9–5.6 2.6–5.8 4.1–7.0 4.0–6.0 4.6–6.0 5.5–8.3
HbA1c (mmol/mol) 26–42 27 23 26 29 NA NA
Ammonia (µmol/L) <45 71 64 50 47 55–99 62–92
Diazoxide (mg/day) – 200 100 100 100 100 200
Chlorthalidone dose – 0 0 0 0 0 Day 1: 50 mg two times per day
Infusion schedule – 10% Glucose 
2 L/24 hours
500 mL Tetrastarch†
Day 1: 5% glucose 2 L/24 hours
Day 2: 5% glucose 1 L/24 hours
Day 3: stop 5% glucose
*Presented as range with lowest and highest value.
†Tetrastarch, 100 mg/mL (10%) hydroxyethyl starch (130/0.4) in isotonic saline.
HbA1c, haemoglobin A1c; NA, not available.
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Personalised labour plan
Preparation
To prevent the spontaneous onset of the delivery, the patient will 
be hospitalised around 39 weeks of gestation. Before labour is 
induced, an arterial line will be placed to monitor glucose levels 
every 20 min and ammonia, sodium and potassium levels every 
3 hours. A central venous catheter will be inserted to guarantee 
intravenous access in case of emergencies.
Labour
A glucose infusion with glucose 10%, 2 L/day, will be adminis-
tered. Patient’s diet will be continued. In case of a glucose level 
<2 mmol/L, an epileptic insult or a hypoglycaemic coma, 50 mL 
50% glucose will be administered immediately.
Post partum
Post partum, a quick recovery of insulin sensitivity is expected 
and glucose levels will be monitored every hour. Plasma 
ammonia- and potassium levels will be monitored every 4 hours.
Lactation
Breastfeeding is discouraged due to the lack of information on 
the use of diazoxide during lactation and the need to further 
increase carbohydrate intake.3
OUTCOME AND FOLLOW-UP
Pregnancy
During the last weeks of the first trimester, the patient presented 
with lowered glucose levels compared with those during 
prepregnancy and hypoglycaemia due to vomiting and insuffi-
cient intake of food and raw cornstarch (table 1). Because of 
hypoglycaemic unawareness, a subcutaneous continuous glucose 
sensor was placed at 11 weeks of gestation. The alert was set to 
sound when glucose levels were below 4.0 mmol/L to prevent 
further decrease. Glycaemic control substantially improved by 
frequent adjustment of the raw cornstarch intake as the preg-
nancy progressed, although the cognitive impairment of the 
patient made it difficult at times for her to adequately respond 
to the glucose monitor alarm.
During the second trimester, no hypoglycaemic events 
occurred (table 1). As nightly tube feeding was refused by the 
patient, a dose of cornstarch in the middle of the night (03:00) 
was added to the regime. The increased intake of carbohydrates 
resulted in a total weight gain during pregnancy of 19.6 kg. The 
mild prepregnancy HA of 71 µmol/L normalised during preg-
nancy (table 1). Fetal growth was evaluated every 2 weeks. The 
estimated fetal weight at 36 weeks of gestational age was 3092 
g (61st percentile).
Labour
The patient was admitted to the obstetric critical care unit at 39 
weeks of gestation for the planned induction of labour. Cervical 
ripening was performed with vaginal administration of miso-
prostol (E1 prostaglandin analogue). During this phase, hypoka-
laemia occurred (2.5 mmol/L) and potassium was supplemented. 
There was one self- limiting episode of HA (99 µmol/L).
Labour was induced by starting oxytocin intravenously and 
glucose 10% infusion was administered continuously. Because 
of suspicion of fetal distress (based on the loss of variability and 
decelerations on fetal heart monitoring) and a failure to prog-
ress, a caesarean section with spinal anaesthesia was performed. 
Glucose levels remained within the normal range during labour 
and delivery, and no complications of the caesarean section 
occurred.
Post partum
Diazoxide 100 mg two times per day and chlorthalidone were 
restarted directly post partum. Glucose infusion was continued, 
subsequently decreased to 5% glucose 2 L/24 hours for the next 
day and thereafter to 1 L/24 hours for one more day (table 1). 
Patient’s hypokalaemia remained (3.3 mmol/L) and potassium 
supplementation was continued for the next 2 days. Cardiolog-
ical and radiological evaluation for an asymptomatic tachycardia 
of 140 bpm showed no abnormalities. Her plasma glucose levels 
were still monitored every hour and electrolytes and ammonia 
levels two times per day. Her ammonia level peaked at 92 µmol/L 
and decreased to 72 µmol/L the next day. The patient was 
discharged with her regular prepregnancy cornstarch diet and 
diazoxide 100 mg two times per day.
Neonatal
A male newborn of 2900 g (13th percentile) was born with Apgar 
scores of 8/8 (1 min/5 min). The umbilical cord gas showed a pH 
of 7.33, a base excess of 0, a glucose level of 4.2 mmol/L and 
an ammonia level of 304 μmol/L (the maximum in neonates is 
100 μmol/L). He did not show any signs of neonatal encepha-
lopathy such as lethargy, irritability, poor tone, absent primitive 
reflexes, seizure activity or feeding difficulties.
Because of respiratory distress and increased C- reactive 
protein after prolonged rupture of the membranes, he was 
admitted to the neonatal ward where continuous positive airway 
pressure (CPAP) was started as well as antibiotics (benzylpeni-
cillin 150 000 IE/kg/day and tobramycin 4 mg/kg/day).
His ammonia level normalised to 96 µmol/L within 12 hours 
without any further intervention. Glucose levels remained 
normal except for two short periods of hypoglycaemia (2.8 
and 2.9 mmol/L) without any need for glucose infusion. The 
CPAP was stopped within 24 hours after which no further clin-
ical symptoms were apparent. Antibiotics were continued for 7 
days on suspicion of a possible perinatal infection. The patient 
was discharged in good clinical condition after blood cultures 
remained negative and his insulin level was 33 pmol/L (normal 
reference <100 pmol/L). Social care was arranged as to support.
GLUD1 mutation analysis demonstrated that the patient 
carried the same mutation as his mother, confirming the diag-
nosis of HI/HA syndrome 2.5 weeks after birth. His insulin level 
had increased to 272 pmol/L by then, with adequate glucose 
levels and no clinical signs of hypoglycaemia. Treatment with 
diazoxide 5 mg/kg/day, hydrochlorothiazide 0.9 mg/kg/day and 
frequent feeding was started immediately. No clinical signs of 
hypoglycaemia have been detected after starting this treatment. 
The patient is now aged 24 months and has shown normal 
growth and development.
Daily monitoring and attendance are given by the parents with 
the support of the grandmother and infant welfare.
DISCUSSION
Insulin and insulin- like growth factors are essential for the regu-
lation of energy metabolism, cell proliferation, tissue develop-
ment and tissue differentiation.
Insulin initiates fetal growth but does not cross the placenta 
because of its molecular weight, indicating that the developing 
fetus is completely dependent on its own insulin production, 
which starts at the end of the first trimester (week 12). Fetal 
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insulin production is strongly stimulated by maternal glucose, 
which does cross the placenta into the fetal circulation.4
As a result, maternal hypoglycaemia could lead to intrauterine 
growth restriction in twofold: directly because of a lack of glucose 
as a nutrient for fetal growth and indirectly because of insuffi-
cient fetal insulin production in response to low glucose levels. 
Even with increased hypoglycaemic episodes, the outcome of 
neonates is favourable with low perinatal mortality and neonatal 
morbidity, as long as hypoglycaemic episodes do not recur too 
often and are of short duration.5
During the first trimester in a normal pregnancy, glucose is 
the most important nutrient for fetal growth and is continuously 
transferred from the maternal blood to the fetus by the placenta.6 
The maternal glucose homeostasis in normal pregnancy, there-
fore, differs from the glucose metabolism before pregnancy; it 
shows transient hyperglycaemia between meals and at night, in 
order to provide for the continuous fetal demand. During the 
first trimester, hyperplasia of the insulin- secreting pancreatic 
β-cells occurs, with resulting increase of insulin secretion and 
a simultaneous increase in insulin sensitivity.7 Mild hypogly-
caemia is a phenomenon seen in a normal pregnancy. Progres-
sive insulin resistance starts to develop in the second trimester, 
peaking during the third trimester due to increased placental 
secretion of human chorionic somatomammotropin (hCS).8 As 
a consequence, insulin resistance quickly disappears after the 
birth of the placenta. With the expulsion of the placenta, the 
production of hCS ceases and due to its short half- life, its effect 
quickly disappears. The rapid return of prepregnancy insulin 
sensitivity can lead to postpartum hypoglycaemia in the situation 
of uncontrolled insulin production such as HI/HA syndrome or 
insulinoma.
HA in adults can lead to encephalopathy and brain oedema.
Interestingly, in adults and neonates with HI/HA syndrome, 
HA- related encephalopathy is not observed and normal 
protein consumption does not further increase ammonia levels. 
Ammonia is formed by renal and pancreatic ammoniagenesis 
due to the enhanced GDH activity. This can be demonstrated 
by ammonia- infusing experiments performed in rats. At mildly 
increased ammonia levels, glutamine synthase activity can be 
enhanced, directly metabolising ammonia in brain cells preventing 
brain oedema and encephalopathy. Another explanation for the 
lack of HA- related encephalopathy in HI/HA syndrome is that 
the actual additional ammonia production is limited and can be 
removed by a normal functioning hepatic urea cycle. Therefore 
glutamine production is not further increased.9 10 As ammonia 
crosses the placenta, maternal HA could contribute to early fetal 
HA, when the fetal urea cycle is yet to develop.
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Learning points
 ► Personalised and multidisciplinary management of pregnancy 
and labour in patients with complex diseases is indispensable.
 ► Lowering the diazoxide dosage and increasing the slow 
absorbing carbohydrate intake, ideally prepregnancy, is 
necessary to prevent both severe hypoglycaemia and 
potential negative effects on fetal growth.
 ► This case provides valuable information on managing 
pregnancies in patients with hyperinsulinaemia and is 
applicable to other conditions such as insulinoma.
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